Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:Ile-Ala-Ser)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST004194 AN006967 PfK13-associated artemisinin resistance slows drug activation and enhances antioxidant defence, which can be overcome with sulforaphane Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST003565 AN005858 Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST003179 AN005222 Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST003144 AN005159 On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity Blood Plasmodium falciparum Malaria Monash University LC-MS
ST003053 AN005006 Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics Bacterial cells Staphylococcus aureus Bacterial infection Monash University LC-MS
ST003053 AN005007 Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics Bacterial cells Staphylococcus aureus Bacterial infection Monash University LC-MS
ST003036 AN004977 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 Bacterial cells Pseudomonas aeruginosa Bacterial infection Monash Institute of Pharmaceutical Sciences LC-MS
ST002792 AN004542 Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002108 AN003448 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002108 AN003449 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002107 AN003446 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002107 AN003447 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST001788 AN002900 β-Adrenergic regulation of metabolism in macrophages (part-IV) Macrophages Human Monash University LC-MS
ST001549 AN002581 β-Adrenergic regulation of metabolism in macrophages (part-III) Macrophages Human Monash University LC-MS
ST001548 AN002579 β-Adrenergic regulation of metabolism in macrophages (part-II) Macrophages Human Monash University LC-MS
ST001547 AN002577 β-Adrenergic regulation of metabolism in macrophages Macrophages Human Monash University LC-MS
ST001304 AN002173 Multi-omics analysis delineates the distinct functions of sub-cellular acetyl-CoA pools in Toxoplasma gondii Fibroblast cells Toxoplasma gondii Parasitic infection Monash University LC-MS
ST001175 AN001951 Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
  logo